EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)

Abstract

Osimertinib is a third generation TKI representing the standard of care for treatment of metastatic NSCLC harboring classical EGFR mutations (exon 19 deletion and L858R). In 10-20% of patients with EGFR alterations, an assorted group of other uncommon mutations can also be detected. These mutations confer variable sensitivity to first- and second-generation TKIs, with overall lower therapeutic activity. Data of Osimertinib in this heterogenous group of mutations are limited and strongly warranted.